“Six-and-twelve” score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort

Table 5 Kaplan-Meier survival analysis according to “Six-and-twelve” score and other systems in the main cohort from Marseille (available data for 241 hepatocellular carcinoma patients)

Scoring/stage systems	OS [95%CI], mo	P value (log-rank)	Sidak1	Hazard ratio [95%CI]	P value
“6&12” score		0.0004
sum ≤ 6 (n = 130)	32 [28-36]		Ref	Ref
sum > 6 ≤ 12 (n = 106)	20 [17-25]		0.0017	1.61 [1.21-2.14]	0.0010
sum > 12 (n = 5)	16 [5-34]		0.0003	3.34 [1.35-8.25]	0.0092
CLIP		< 0.0001
0 (n = 55)	35 [30-68]		Ref	Ref
1 (n = 135)	28 [25-32]		0.0724	1.81 [1.23-2.67]	0.0028
2 (n = 45)	18 [15-23]		< 0.0001	2.86 [1.81-4.54]	< 0.0001
3 (n = 6)	10 [1-27]		< 0.0001	8.12 [3.35-19.67]	< 0.0001
HKLC		< 0.0001
1 (n = 89)	36 [30-40]		Ref	Ref
2a (n = 42)	25 [19-35]		0.0024	1.79 [1.18-2.72]	0.0060
2b (n = 65)	26 [19-34]		0.0749	1.45 [1.01-2.10]	0.0450
3a (n = 24)	17 [11-23]		< 0.0001	3.30 [2.03-5.36]	< 0.0001
3b (n = 21)	14 [11-16]		< 0.0001	4.55 [2.73-7.58]	< 0.0001
Up-to-Seven		0.0001
In (n = 176)	30 [27-35]		NA	Ref
Out (n = 65)	18 [15-24]		NA	1.81 [1.34-2.46]	0.0001
MESH		< 0.0001
0 (n = 41)	43 [35-70]		Ref	Ref
1 (n = 77)	30 [25-35]		0.1291	2.16 [1.33-3.48]	0.0017
2 (n = 78)	26 [19-34]		0.0490	2.30 [1.41-3.74]	0.0008
3 (n = 37)	15 [10-21]		< 0.0001	6.02 [3.51-10.33]	< 0.0001
4 (n = 8)	13 [4-24]		< 0.0001	9.69 [3.86-24.36]	< 0.0001

¹Sidak test for multiple comparisons. “6&12”: “Six-and-twelve”; OS: Overall Survival; CI: Confidence Interval; Ref: Reference; CLIP: Cancer of the Liver Italian Program; HKLC: Hong Kong Liver Cancer; MESH: Model to Estimate Survival for Hepatocellular carcinoma.